| Cash Flow | 2025-09-30 | 2025-07-31 |
|---|---|---|
| Product revenue, net | 13,692 | - |
| Total operating expenses | 168,436 | - |
| Operating loss | -154,744 | - |
| Other (expense) income | 1,379 | - |
| Loss before income tax expense | -153,365 | - |
| Income tax expense | 5,549 | - |
| Net loss | -158,914 | -60,096 |
| Depreciation and amortization | 867 | 252 |
| Stock-based compensation expense | 12,232 | 5,379 |
| Realized gain from sale of marketable securities | 1,752 | 587 |
| Non-cash operating lease expense (benefit) | - | 218 |
| Non cash operating lease expense | -33 | - |
| Amortization of premium on marketable securities | 22 | -7 |
| Foreign currency exchange loss (gain) | 6,879 | -485 |
| Non-cash interest expense and amortization of issuance costs | 10,569 | 3,453 |
| Fair value adjustment to derivative liability | -1,306 | -1,100 |
| Impairment of right of use assets | 1,190 | - |
| Research and development tax credit receivable | -10,616 | -826 |
| Accounts receivable, net | 5,779 | 1,926 |
| Inventory | 457 | - |
| Prepaid expenses and other assets | 3,163 | -1,597 |
| Accounts payable | 6,093 | 2,510 |
| Accrued expenses | - | -8,199 |
| Accrued expenses and other liabilities | -4,154 | - |
| Deferred revenue | 11,251 | 493 |
| Net cash used in operating activities | -126,985 | -54,502 |
| Purchases of marketable securities | 105,772 | 19,979 |
| Sales and maturities of marketable securities | 127,889 | 41,677 |
| Acquisition of property and equipment | 1,863 | 290 |
| Disposal of property and equipment | 12 | - |
| Capitalized website development costs | 394 | 147 |
| Net cash provided by (used in) investing activities | 19,872 | 21,261 |
| Proceeds from sale of convertible notes | 139,438 | - |
| Proceeds from the royalty agreement | 21,259 | 21,921 |
| Issuance of common stock from equity incentive plans | 2,539 | 595 |
| Issuance of common stock from employee stock purchase plan | 1,154 | 694 |
| Net cash provided by financing activities | 164,390 | 23,210 |
| Effect of exchange rate changes | 4,042 | 2,723 |
| Net increase in cash, cash equivalents and restricted cash | 61,319 | -7,308 |
| Cash and cash equivalents at beginning of period | 182,978 | - |
| Cash and cash equivalents at end of period | 244,297 | - |
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)